Cannabis and medicinal mushrooms could “improve effectiveness” of cancer treatment

A Canadian pharmaceutical company is combining medical cannabis with medicinal mushroom compounds to treat serious diseases, including cancer. 

Canadian pharmaceutical company, Aion Therapeutic Inc has filed four new patent applications related to preparations of medicinal cannabis and psychedelic mushrooms. 

The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations. 

Aion is an international pharmaceutical company specialising in combining the healing powers of medical cannabis and medicinal mushroom compounds to create a new class of therapeutics which it believes could lead to a “paradigm shift” in global healthcare. 

“Based on these recent discoveries, we believe that it may be possible to improve upon the effectiveness of standard treatments for certain cancers including breast cancer as well as offering a new therapy for the painful chronic condition known as interstitial cystitis,” said Dr. Herbert A. Fritsche, chief science officer of Aion Therapeutic and former professor and director of Clinical Chemistry at the University of Texas, MD Anderson Cancer Center.

“We intend to announce the details of these very exciting discoveries now that the patents have been filed.”

Graham Simmonds, executive vice chair and CEO of Aion Therapeutic, commented: “I commend our medical and science teams, led by Dr Stephen Barnhill and Dr Herbert Fritsche for creating a robust intellectual property portfolio based on a sound patent strategy. 

“In conjunction with our licensed medical cannabis partner Apollon Formularies Jamaica, Ltd, Aion is leveraging our unique position in a powerful way to combine medical cannabis and medicinal mushroom compounds for the treatment of serious diseases including cancer.” 

In addition, Aion will also be utilising psilocybin with certain cannabinoids to treat additional conditions such as major depressive disorder (MDD) at its Aion Center for Psychedelic Psychiatry directed by Dr. Winston De La Haye in Jamaica. 

Mr Simmonds continued: “Strategically locating our operations in Jamaica allows Aion to operate and conduct clinical trials in a federally legal environment and thereby having a significant head start on patentable therapeutic formulation discoveries combining mushrooms (including psilocybin) and tetrahydrocannabinol (THC) with other medicinal mushroom and medical cannabis compounds while this type of combinatorial research with psilocybin remains illegal in most of the world.”